Publications

  1. Zamora AC, Wesselius LJ, Gotway MB, Tazelaar HD, Diaz-Arumir A, Nagaraja V. Diagnostic Approach to Interstitial Lung Diseases Associated with Connective Tissue Diseases. Semin Respir Crit Care Med. 2024 Jun; 45 (3):287-304 Epub 2024 Apr 17
    View PubMed
  2. Aragon Sierra AM, Hwang AS, Kechter J, Mangold AR, Nagaraja V, DiCaudo DJ. Systemic sclerosis with morphea-like plaques histopathologically mimicking cutaneous B-cell lymphoma. JAAD Case Rep. 2024 May; 47:32-34 Epub 2024 Mar 08
    View PubMed
  3. Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyznski P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP, RESOLVE-1 Study Group. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 Sep; 75 (9):1608-1618 Epub 2023 June 15
    View PubMed
  4. Makol A, Nagaraja V, Amadi C, Pugashetti JV, Caoili E, Khanna D. Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol. 2023 Jun; 19 (6):613-626 Epub 2023 Apr 10
    View PubMed
  5. McBride N, Swaminathan S, Nagaraja V. A 64-Year-Old Man with Joint Pain. NEJM Evid. 2023 Jun; 2 (6):EVIDmr2200337 Epub 2023 May 23
    View PubMed
  6. Roofeh D, Brown KK, Kazerooni EA, Tashkin D, Assassi S, Martinez F, Wells AU, Raghu G, Denton CP, Chung L, Hoffmann-Vold AM, Distler O, Johannson KA, Allanore Y, Matteson EL, Kawano-Dourado L, Pauling JD, Seibold JR, Volkmann ER, Walsh SLF, Oddis CV, White ES, Barratt SL, Bernstein EJ, Domsic RT, Dellaripa PF, Conway R, Rosas I, Bhatt N, Hsu V, Ingegnoli F, Kahaleh B, Garcha P, Gupta N, Khanna S, Korsten P, Lin C, Mathai SC, Strand V, Doyle TJ, Steen V, Zoz DF, Ovalles-Bonilla J, Rodriguez-Pinto I, Shenoy PD, Lewandoski A, Belloli E, Lescoat A, Nagaraja V, Ye W, Huang S, Maher T, Khanna D. Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. Rheumatology (Oxford). 2023 May 2; 62 (5):1877-1886
    View PubMed
  7. Domsic RT, Pokrzywinski R, Stassek L, Benton WW, Vampola CL, Furst DE, Chung L, Steen V, Mayes MD, Shah AA, Molitor JA, Oliver K, Nagaraja V, Khanna D. Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis. ACR Open Rheumatol. 2023 Mar; 5 (3):132-141 Epub 2023 Feb 02
    View PubMed
  8. Wang B, Nagaraja V. Diagnosis and Management of Patients with Connective Tissue Disease-related Fibrosing Interstitial Lung Diseases. Open Respir Med J. 2023; 17:e187430642306150 Epub 2023 Aug 15
    View PubMed
  9. Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO, TRAIL1 Network Investigators. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023 Jan; 11 (1):87-96 Epub 2022 Sept 05
    View PubMed
  10. Weiner JK, Smith T, Hoy CK, Sarosh C, Madison JA, Ambati A, Tambralli A, Peters N, Packel C, Gockman K, Zuo Y, Briceno EM, Nagaraja V, Knight JS. Predictors and Interrelationship of Patient-Reported Outcomes in Antiphospholipid Syndrome: A Cross-Sectional Study. ACR Open Rheumatol. 2023 Jan; 5 (1):28-37 Epub 2022 Dec 02
    View PubMed
  11. Ramahi A, Lescoat A, Roofeh D, Nagaraja V, Namas R, Huang S, Varga J, O'Dwyer D, Wang B, Flaherty K, Kazerooni E, Khanna D. Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-center cohort. Rheumatology (Oxford). 2022 Nov 15 [Epub ahead of print]
    View PubMed
  12. Khanna D, Padilla C, Tsoi LC, Nagaraja V, Khanna PP, Tabib T, Kahlenberg JM, Young A, Huang S, Gudjonsson JE, Fox DA, Lafyatis R. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. JCI Insight. 2022 Sep 8; 7 (17) Epub 2022 Sept 08
    View PubMed
  13. O'Dwyer DN, Wang BR, Nagaraja V, Flaherty KR, Khanna D, Murray S, Mari PV, White ES. Hypothyroidism Is Associated with Increased Mortality in Interstitial Pneumonia with Autoimmune Features. Ann Am Thorac Soc. 2022 May 19 [Epub ahead of print]
    View PubMed
  14. Young A, Moles VM, Jaafar S, Visovatti S, Huang S, Vummidi D, Nagaraja V, McLaughlin V, Khanna D. Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis Rheumatol. 2021 Sep; 73(9):1731-1737. Epub 2021 Jul 27.
    View PubMed
  15. Sankar S, Habib M, Jaafar S, Nagaraja V, Roofeh D, Young A, Huang S, Khanna D. Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. Clin Exp Rheumatol. 2021 Jul-Aug; 39 Suppl 131 (4):43-51 Epub 2021 Mar 10
    View PubMed
  16. Jaafar S, Lescoat A, Huang S, Gordon J, Hinchcliff M, Shah AA, Assassi S, Domsic R, Bernstein EJ, Steen V, Elliott S, Hant F, Castelino FV, Shanmugam VK, Correia C, Varga J, Nagaraja V, Roofeh D, Frech T, Khanna D. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther. 2021 Jun 14; 23 (1):170 Epub 2021 June 14
    View PubMed
  17. Huang S, Kronzer VL, Dellaripa PF, Deane KD, Bolster MB, Nagaraja V, Khanna D, Doyle TJ, Sparks JA. Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. Curr Treatm Opt Rheumatol. 2020 Dec; 6(4):337-353. Epub 2020 Sep 01.
    View PubMed
  18. Chung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, Steen VD, Lafyatis R, Simms RW, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Sandorfi N, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Allanore Y, Matucci-Cerinic M, Whitfield ML, Distler O, Singer O, Young A, Nagaraja V, Fox DA, Furst DE, Khanna D. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol. 2020 Dec; 2 (12):e743-e753 Epub 2020 Oct 19
    View PubMed
  19. Murphy S, Krause D, Welsh E, Lyden A, Barber M, Sabbah M, Nagaraja V, Bush E, Poole J, Khanna D. Adherence to upper-extremity home exercise delivered via mobile app for people with systemic sclerosis. American Journal of Occupational Therapy. 2020 Aug; 74(4_Supplement_1):7411520489p1.
  20. Nagaraja V, Matucci-Cerinic M, Furst DE, Kuwana M, Allanore Y, Denton CP, Raghu G, Mclaughlin V, Rao PS, Seibold JR, Pauling JD, Whitfield ML, Khanna D. Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis Rheumatol. 2020 Jul; 72 (7):1049-1058 Epub 2020 May 18
    View PubMed
  21. Homer KL, Warren J, Karayev D, Khanna PP, Young A, Nagaraja V, Metzger AL, Khanna D. Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. J Clin Rheumatol. 2020 Apr; 26 (3):115-118
    View PubMed
  22. Nagaraja V, Spino C, Bush E, Tsou PS, Domsic RT, Lafyatis R, Frech T, Gordon JK, Steen VD, Khanna D. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Res Ther. 2019 Sep 3; 21 (1):202 Epub 2019 Sept 03
    View PubMed
  23. Fisher CJ, Namas R, Seelman D, Jaafar S, Homer K, Wilhalme H, Young A, Nagaraja V, White ES, Schiopu E, Flaherty K, Khanna D. Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol. 2019 Jul-Aug; 37 Suppl 119 (4):49-56 Epub 2019 Sept 04
    View PubMed
  24. Pauling JD, Nagaraja V, Khanna D. Insight into the contrasting findings of therapeutic trials of digital ischaemic manifestations of systemic sclerosis. Curr Treat Options in Rheum. 2019 Jun 15; 5(2):85-103.
  25. Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. Semin Arthritis Rheum. 2019 Jun; 48 (6):1059-1067 Epub 2018 Oct 14
    View PubMed
  26. Nagaraja V. Management of scleroderma renal crisis. Curr Opin Rheumatol. 2019 May; 31 (3):223-230
    View PubMed
  27. Matucci-Cerinic C, Nagaraja V, Prignano F, Kahaleh B, Bellando-Randone S. The role of the dermatologist in Raynaud's phenomenon: a clinical challenge. J Eur Acad Dermatol Venereol. 2018 Jul; 32 (7):1120-1127 Epub 2018 Apr 11
    View PubMed
  28. Nagaraja V, Mara C, Khanna PP, Namas R, Young A, Fox DA, Laing T, McCune WJ, Dodge C, Rizzo D, Almackenzie M, Khanna D. Establishing clinical severity for PROMIS((R)) measures in adult patients with rheumatic diseases. Qual Life Res. 2018 Mar; 27 (3):755-764 Epub 2017 Oct 05
    View PubMed
  29. Nagaraja V, Khanna D. Screening and management of pulmonary arterial hypertension in systemic sclerosis. Indian Journal of Rheumatology. 2017 Nov; 12(6 Supplement):204-10.
  30. Chalhoub NE, Kaw D, Nagaraja V. A Man With a Nonblanchable Purpuric Rash. JAMA. 2017 Jun 13; 317 (22):2329-2330
    View PubMed
  31. Khanna D, Nagaraja V, Tseng CH, Abtin F, Suh R, Kim G, Wells A, Furst DE, Clements PJ, Roth MD, Tashkin DP, Goldin J. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther. 2015 Dec 23; 17:372
    View PubMed
  32. Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford). 2015 Nov; 54 (11):1944-53 Epub 2014 July 26
    View PubMed
  33. McCoy S, Nagaraja V, Paviol S, Gudjonsson JE, Kahlenberg JM. Exacerbation of psoriasis due to hydroxychloroquine. Arch Med. 2015; 7:1-3.
  34. Nagaraja V, McMahan ZH, Getzug T, Khanna D. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol. 2015 Mar 1; 1 (1):82-105
    View PubMed
  35. Nagaraja V, Hays RD, Khanna PP, Spiegel BM, Chang L, Melmed GY, Bolus R, Khanna D. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. Arthritis Care Res (Hoboken). 2014 Nov; 66 (11):1725-30
    View PubMed
  36. Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol. 2013 Nov; 25 (6):700-6
    View PubMed
  37. Prabhakaran S, Doraiswamy VA, Nagaraja V, Cipolla J, Ofurum U, Evans DC, Lindsey DE, Seamon MJ, Kavuturu S, Gerlach AT, Jaik NP, Eiferman DS, Papadimos TJ, Adolph MD, Cook CH, Stawicki SP. Nasoenteric tube complications. Scand J Surg. 2012; 101 (3):147-55
    View PubMed
  38. Smith BP, Adams RC, Doraiswamy VA, Nagaraja V, Seamon MJ, Wisler J, Cipolla J, Sharma R, Cook CH, Gunter OL, Stawicki SP. Review of abdominal damage control and open abdomens: focus on gastrointestinal complications. J Gastrointestin Liver Dis. 2010 Dec; 19 (4):425-35
    View PubMed
  39. Nagaraja V, Terriquez JA, Gavini H, Jha L, Klotz SA. Pulmonary Embolism Mimicking Pneumonia in a HIV Patient. Case Rep Med. 2010; 2010:394546 Epub 2010 June 14
    View PubMed